MYDRIACYL
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Feb 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MYDRIACYL by Alcon is clinical pharmacology this anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the ciliary muscle to cholinergic stimulation, dilating the pupil (mydriasis). First approved in 1960.
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYDRIACYL is a topical anticholinergic ophthalmic solution that produces mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation) by blocking cholinergic stimulation of the iris sphincter and ciliary muscles. It is used in ophthalmology for diagnostic and therapeutic procedures requiring pupil dilation. The 1% formulation provides stronger cycloplegia than the weaker preparation, with onset in 15-30 minutes and duration of 3-8 hours.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); brand team likely focused on maintaining share against generic and therapeutic alternatives in a mature market segment.
Mechanism of Action
CLINICAL PHARMACOLOGY This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the ciliary muscle to cholinergic stimulation, dilating the pupil (mydriasis). The stronger preparation (1%) also paralyzes accommodation. This preparation acts in 15-30 minutes, and…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MYDRIACYL in a LOE-approaching environment offers experience in defensive brand strategy, generic competition management, and portfolio optimization within the ophthalmology segment. Roles focus on operational efficiency and market access rather than clinical innovation.
Brand Manager
Worked on MYDRIACYL at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.